Unfractionated heparin is the most potent and frequently administered intravenous anticoagulant for patients who require rapid-onset systemic anticoagulation 1,2 . The most thrombogenic indication for UFH is CPB surgery, which is performed annually on more than one million patients worldwide 2 . CPB surgery triggers fulminant activation of both the intrinsic (contact-mediated) and extrinsic (tissue factor-mediated) coagulation pathways due to extracorporeal blood circulation and surgical trauma, respectively 3-5 . UFH achieves its robust anticoagulant effect through an indirect mechanism mediated by antithrombin (AT), and it accelerates AT-mediated irreversible inhibition of multiple procoagulant proteases, including thrombin and factors Xa, IXa, VIIa and XIa 2,6,7 . However, UFH has several limitations that contribute to morbidity and mortality associated with CPB 2-4,7-12 .
A r t i c l e s
Unfractionated heparin is the most potent and frequently administered intravenous anticoagulant for patients who require rapid-onset systemic anticoagulation 1, 2 . The most thrombogenic indication for UFH is CPB surgery, which is performed annually on more than one million patients worldwide 2 . CPB surgery triggers fulminant activation of both the intrinsic (contact-mediated) and extrinsic (tissue factor-mediated) coagulation pathways due to extracorporeal blood circulation and surgical trauma, respectively [3] [4] [5] . UFH achieves its robust anticoagulant effect through an indirect mechanism mediated by antithrombin (AT), and it accelerates AT-mediated irreversible inhibition of multiple procoagulant proteases, including thrombin and factors Xa, IXa, VIIa and XIa 2, 6, 7 . However, UFH has several limitations that contribute to morbidity and mortality associated with CPB [2] [3] [4] [7] [8] [9] [10] [11] [12] .
The major drawbacks of UFH-facilitated CPB include the finding that UFH cannot prevent continuous generation of thrombin during CPB, partly due to its ineffectiveness in inhibiting either FXa activity within prothrombinase or clot-bound thrombin 3, 4, 8, 13, 14 . Not only does thrombin generation exacerbate thrombotic and inflammatory complications of CPB, but the resultant coagulation factor and platelet consumption also predispose the patient to post-operative bleeding 4, 11, [15] [16] [17] . UFH's depletion of AT during CPB can also diminish its efficacy, leading to heparin resistance 3, 7, 18 . Prolonged or repeated exposure to UFH can trigger heparin-induced thrombocytopenia (HIT), a potentially life-threatening antibody-mediated thrombotic syndrome 3, 19 . Moreover, UFH's antidote, protamine, is associated with several toxicities, and despite its routine administration for UFH reversal, post-operative bleeding remains a major adverse event after CPB surgery 3, 10, 11, 20, 21 . Thus, a potent, antidotecontrollable anticoagulant alternative to UFH without these limitations remains an unmet medical need.
Because UFH's efficacy lies in its multimodal ability to enhance inhibition of thrombin and the proteinases responsible for thrombin formation [22] [23] [24] , an anticoagulation strategy intended to match UFH's potency will also likely need to act at multiple steps that lead to thrombin formation. We previously identified an anticoagulant RNA aptamer, 11F7t, that binds a FXa exosite and the corresponding FX pro-exosite 25 . 11F7t inhibits prothrombinase formation by inhibiting (i) the binding of FXa to FVa, (ii) FXa-catalyzed cleavage of FVIII and (iii) activation of FX by intrinsic tenase 25 . Through these multiple mechanisms, 11F7t achieves a substantial anticoagulant effect, although it is less potent than UFH's 25, 26 . Here we tested whether addition of a FXa active site inhibitor might augment the anticoagulant intensity of 11F7t. Active site inhibitors of FXa-which include the small-molecule drugs rivaroxaban, apixaban and edoxaban-are already clinically approved 27 . We also investigated whether the combination of 11F7t plus a FXa active site inhibitor could be effectively and concomitantly neutralized by GD-FXa Ser195Ala , an inactive FXa variant that resembles an antidote for FXa inhibitors (andexanet alfa), which recently received clinical approval in the USA [28] [29] [30] .
combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass A r t i c l e s RESULTS Structure of aptamer 11F7t bound to GD-FXa Ser195Ala We determined a high-resolution X-ray structure of 11F7t complexed with GD-FXa Ser195Ala , a FXa variant that lacks the membrane binding γ-carboxyglutamic acid (Gla) domain and contains an alanine substitution at the catalytic serine (Fig. 1a, Supplementary Fig.1a and Supplementary Table 1) . We used molecular replacement to solve the structure at 2.0-Å resolution and found the following. The tertiary fold of 11F7t presents an extended molecular surface for interactions with GD-FXa Ser195Ala , with ~1,400 Å 2 of solvent-accessible surface area buried within the complex. Contacts between the aptamer and the protein are specified by 15 hydrogen bonds with nucleotide bases in a central loop encompassing C8, A10, A21, C28-C30 and proteinase domain residues Leu59, Arg64, Val88, Iso89, Asn92, Arg93, Lys236 and Arg240 (Supplementary Fig. 1a ). This broad surface includes residues that are implicated in heparin binding and in FVa binding, based on modest changes in function that have been observed after mutagenesis 31 .
11F7t binding did not seem to occlude the catalytic triad or access to the S1 binding pocket. Consistent with this observation, we were also able to crystallize and solve the structure of a ternary complex between GD-FXa Ser195Ala , 11F7t and rivaroxaban bound to the active site of the proteinase at 2.25-Å resolution (Fig. 1b, Supplementary  Fig. 1b and Supplementary Table 1 ). The proteinase-aptamer complex in the two structures were essentially identical (root mean square (r.m.s.) deviation = 0.17 Å), as was the proteinase-rivaroxaban component within the ternary complex and a previously published structure of FXa bound to rivaroxaban (r.m.s. deviation = 0.29 Å) 32 . Therefore, 11F7t and the active site ligand likely bind independently to FXa to separately inhibit macromolecular interactions and catalytic function. Structural evidence indicates that rivaroxaban and apixaban bind to FXa in a very similar way and that both are also chemically analogous to the third FXa active site inhibitor, edoxaban, which has been approved for clinical use 27, 33 .
The interface between 11F7t and FXa is distant from the 165 helix of the proteinase domain, which was previously proposed to be essential for its binding to FVa 31 and also implicated in the interaction of FVIIa and FIXa with their respective cofactors. A minimal two-part interaction between proteinase and cofactor is implied by the recent structure of the snake venom orthologs of FV bound in solution to FX from Pseudonaja textilis 34 . In addition to contacts between the 165 helix and the body of the FV component, an additional and extensive contact is made by a peptide from the C terminus of the A2 domain of FV extending across a second face of the proteinase domain distant from this helix 34 . Superposition of the structure of GD-FXa Ser195Ala bound to 11F7t with the snake venom structure ( Supplementary  Fig. 2 and Supplementary Note) revealed that the aptamer occupied the same surface as the A2 polypeptide from snake venom FV. If such comparisons have merit, then they imply a comparable interaction between an acidic sequence at the C terminus of the A2 domain of FVa and an extended surface encompassing the heparin-binding face of the proteinase domain of FXa. Despite additional interactions between proteinase and cofactor, occlusion of this surface by 11F7t is sufficient to reduce the affinity of FXa for FVa to an undetectable level 25 (Supplementary Note).
Potentiated inhibition of thrombin formation
To assess whether the structural findings correctly predicted that inhibition by 11F7t may be potentiated if paired with an active sitedirected inhibitor of FXa, we measured the effects of each anticoagulant, alone or in combination, using systems of thrombin generation of increasing complexity. We used reaction mixtures that contained prothrombin, FVa and phospholipid membranes and in which thrombin formation was initiated by FXa addition. The robust initial velocity of thrombin formation observed in the absence of inhibitors was partially inhibited by apixaban or 11F7t added individually, but the extent of inhibition was far greater (>90%) when both apixaban and 11F7t were present (Fig. 2a,b) .
We then measured thrombin formation in reaction mixtures that contained prothrombin, FX, FVa and FVIII and that was supplemented with membranes and initiated by the addition of FIXa (Fig. 2c) . In the absence of an anticoagulant, the time required for the formation of 10 nM thrombin following initiation with FIXa was approximately 0.5 min (Fig. 2d) . Although treatment with apixaban or 11F7t alone prolonged that interval significantly (~1 and 4 min, respectively), the largest prolongation, to >11 min, was seen in the combined presence of 11F7t plus apixaban (Fig. 2d) . Similarly, treatment with a combination of apixaban and 11F7t produced a notable 99% inhibition of thrombin formation 10 min after initiation (Fig. 2e) .
Inhibitor neutralization
Two independent strategies have been used to neutralize the anticoagulant effects of active site-directed inhibitors of FXa and of inhibitory aptamers targeting coagulation enzymes. The first uses a catalytically inactive decoy protein, such as GD-FXa Ser195Ala , capable of engaging inhibitors at the active site but unable to bind phospholipid membranes and FVa with high affinity 28 . In this case, GD-FXa Ser195Ala scavenges the circulating inhibitor, without interfering with the function of endogenous FXa, to restore normal clotting. In the second, sequencespecific complementary oligonucleotides are used to disrupt aptamer secondary structure and binding to its target 35 . We compared the ability of the 11F7t-specific antidote oligonucleotide AO5-2 (ref. 36) and GD-FXa Ser195Ala to reverse the anticoagulant effect produced by treatment with 11F7t plus apixaban in the FIXa-triggered model of thrombin generation (Fig. 2f) . Treatment with AO5-2 partially restored thrombin generation to levels similar to those observed in the presence of apixaban alone, in accord with its specific neutralization of aptamer-dependent inhibition. In contrast, the presence of GDFXa Ser195Ala completely reversed the inhibitory effects of both 11F7t and apixaban and restored thrombin generation to levels observed in the absence of an anticoagulant. a b Figure 1 X-ray crystal structures of aptamer 11F7t bound to GD-FXa Ser195Ala .
Structures were solved both in the absence (a) and presence (b) of rivaroxaban. The proteinase domain of GD-FXa Ser195Ala is depicted in the standard orientation. Residues that comprise the catalytic site are illustrated as red sticks, and residues that form hydrogen bonds with 11F7t are denoted as blue sticks. Bound Na + (purple), Ca 2+ (green) and rivaroxaban (yellow) are rendered as spheres.
A r t i c l e s
Inhibition of tissue factor-initiated thrombin generation The reconstituted systems described above assess inhibition of thrombin formation but do not include the contribution of FX activation by the FVIIa-tissue factor (TF) pathway. Because a viable anticoagulation strategy for CPB surgery must inhibit both extrinsic and intrinsic hemostatic activation, we compared the ability of UFH with that of 11F7t plus a FXa active site inhibitor to limit thrombin generation triggered by adding TF to platelet-rich plasma (PRP) in 'calibrated automated thrombogram' (CAT) assays 36 . In the absence of an anticoagulant, addition of 50 pM TF to PRP elicited a robust rise and fall in active thrombin concentration over the ensuing 60 min, reflecting thrombin's formation by procoagulant proteinases and its subsequent inactivation by plasma serpins (Fig. 3a) . The area under the curve, which reflects the total amount of thrombin generated over time and is referred to as the endogenous thrombin potential (ETP) 36 , was 1,789.0 ± 119.7 nM·min (mean ± s.e.m.). The presence of either UFH alone, 11F7t alone or a FXa active site inhibitor (rivaroxaban, apixaban or edoxaban) alone resulted in a concentration-dependent decrease in the ETP (Supplementary Fig. 3a,b) . The presence of 5 U/ml UFH, the approximate circulating concentration during clinical CPB, reduced the ETP and thrombin generation to undetectable levels in all of the assays (Fig. 3a,b) . In comparison, 2 µM 11F7t alone, 2 µM rivaroxaban alone, 2 µM apixaban alone or 2 µM edoxaban alone only modestly reduced the ETP to 995.5 ± 263.0 nM·min, 1,251.6 ± 97.4 nM·min, 1,041.5 ± 181.1 nM·min and 1,137.2 ± 169.7 nM·min, respectively (Fig. 3a,b and Supplementary  Fig. 3b ). Equimolar combinations of 11F7t and each FXa active site inhibitor (at 0.25 µM or 0.5 µM) reduced the ETP to levels lower than those observed with each inhibitor alone at the same concentrations, but they did not completely prevent thrombin production ( Supplementary Fig. 4 ). However, the 1 µM combination of 11F7t plus rivaroxaban, apixaban or edoxaban completely abrogated thrombin generation, diminishing the ETP to undetectable levels similar to those seen after treatment with 5 U/ml UFH (Fig. 3a,b) . In addition to these inhibitory effects on the ETP, similar trends were also observed with respect to other parameters of thrombin generation evaluated by CAT analysis, such as the thrombin lag time, peak thrombin concentration and time-to-peak thrombin production 36 (Supplementary Table 2) . or the same anticoagulation strategies tested in the FXa-initiated system in a,b (i.e., 20 nM apixaban alone (n = 6 independent experiments), 2 µM 11F7t alone (n = 5 independent experiments) or 20 nM apixaban plus 2 µM 11F7t (n = 6 independent experiments)), as well as the effect of GD-FXa Ser195Ala (GD-FXa S195A ; 2 µM) or the 11F7t-specific antidote oligonucleotide AO5-2 (10 µM) on neutralization of 2 µM 11F7t plus 20 nM apixaban in the FIXa-initiated system of thrombin generation (n = 2 independent experiments). The same concentration of GD-FXa Ser195Ala did not appreciably affect thrombin formation when added in the absence of anticoagulants. Throughout, the data are presented as mean ± s.e.m. Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by Tukey's multiple-comparisons test.
Anticoagulation of whole blood Next we compared the anticoagulant efficacy of 11F7t, alone and in combination with an active site-directed FXa inhibitor, with that of UFH in whole blood using thromboelastography (TEG) 37 . This assay measures time-dependent, viscoelastic parameters of clot formation after coagulation is triggered by addition of kaolin to stimulate activation of the contact (intrinsic) pathway 37 . In control TEG assays performed on non-anticoagulated whole blood from healthy donors, the time between kaolin addition and detectable clot formation was 7.1 ± 0.2 min (mean ± s.e.m.) ( Fig. 3c,d ). The presence of 5 U/ml UFH prolonged the TEG clotting time to >180 min in each assay ( Fig. 3c,d ). When added individually, 11F7t, rivaroxaban or edoxaban each prolonged the TEG clotting time in a dose-dependent manner ( Supplementary Fig. 5a-c ), but to a lesser extent than that observed with UFH. For example, the presence of 2 µM 11F7t, 2 µM rivaroxaban or 2 µM edoxaban increased the TEG clotting time to 40.1 ± 4.7 min, 21.0 ± 1.9 min and 23.1 ± 3.3 min, respectively (Fig. 3b) . Equimolar concentrations of 11F7t and either rivaroxaban or edoxaban, at 0.5 µM or 1.0 µM, prolonged the TEG clotting time to a significantly greater degree than that observed with each inhibitor alone at the same concentrations, but not to the same extent as that observed in the presence of 5 U/ml UFH ( Supplementary  Fig. 5d,e) . However, the combined presence of 2 µM 11F7t plus either 2 µM rivaroxaban or 2 µM edoxaban each prolonged the TEG clotting time to >180 min in all of the samples tested (Fig. 3c,d ).
In addition to the inhibitory effects on the clotting time, analogous patterns were also noted with regard to other viscoelastic properties of clot formation measured by TEG analysis, such as the maximum amplitude and α angle, which reflect the clot strength and rate of formation, respectively 37 (Supplementary Table 3 ). Hence, even in Undetectable levels Figure 3 Inhibitory effects of 11F7t and a FXa catalytic site inhibitor. (a,b) CAT assays were performed to measure thrombin generation in platelet rich plasma (150,000 platelets/µl) following addition of 50 pM TF in the absence of an anticoagulant (n = 6 independent experiments) or in the presence of one of the following anticoagulation strategies: 2 µM 11F7t (n = 3 independent experiments), 2 µM rivaroxaban (Riva) (n = 3 independent experiments), 2 µM apixaban (Apix) (n = 3 independent experiments), 1 µM 11F7t plus 1 µM rivaroxaban (n = 3 independent experiments), 1 µM 11F7t plus 1 µM apixaban (n = 3 independent experiments) or 5 U/ml UFH (n = 4 independent experiments). Representative mean CAT tracings (a) and the computed endogenous thrombin potential (ETP) or area under the curve (b) for each condition are plotted. (c,d) TEG assays were performed on human whole blood containing no anticoagulant (n = 126 independent experiments) or subjected to one of the following anticoagulation strategies: 2 µM 11F7t (n = 17 independent experiments), 2 µM rivaroxaban (n = 6 independent experiments), 2 µM edoxaban (Edox) (n = 4 independent experiments), 2 µM 11F7t plus 2 µM rivaroxaban (n = 4 independent experiments), 2 µM 11F7t plus 2 µM edoxaban (n = 7 independent experiments) or 5 U/ml UFH (n = 4 independent experiments). Representative TEG tracings (c) and the time until detectable clot formation following kaolin-initiated coagulation for each condition (d) are depicted, with the maximum time limit of a TEG assay being 180 min. Throughout, the data are presented as mean ± s.e.m. *P < 0.05; n.s., not significant; by one-way ANOVA followed by Tukey's multiple-comparisons test. Exact P values in b,d are provided as follows:
, and d(6) versus d (7), P > 0.9999.
A r t i c l e s whole blood, the aptamer and active site-directed inhibitors of FXa yield a combined inhibitory effect that can match the anticoagulant potency achieved by UFH.
For comparison, we also similarly evaluated the effects of bivalirudin, a direct thrombin inhibitor that is occasionally used as an alternative for CPB anticoagulation in patients with severe contraindications to UFH, such as HIT 2, 3 . However, bivalirudin is used very cautiously because its use during CPB surgery is associated with a notable risk of clotting in areas prone to blood pooling, such as the operative field or CPB circuit 2, 3 . Consistent with its weaker potency, even at supra-therapeutic concentrations as high as 36.7 µM, bivalirudin only extended the TEG clotting time to 34.3 ± 4.1 min (Supplementary Fig. 6 ).
Anticoagulation during extracorporeal circulation
The anticoagulant efficacy of 11F7t plus a FXa active site inhibitor that was evident from the CAT and TEG studies suggested that this combination of anticoagulants might also achieve anticoagulation potent enough to facilitate CPB surgery. To begin to assess this possibility, we tested the ability of this dual FXa anticoagulant approach to prevent clot formation in fresh human blood subjected to a 2-h period of continuous recirculation within an ex vivo circuit that included a membrane oxygenator 26 . The activated clotting time (ACT) assay is used to assess the adequacy of anticoagulation during CPB 2 . The normal ACT range is 100 to 125 s, whereas an ACT range of 400 to 480 s in the presence of UFH is considered to be therapeutic for CPB 2 . As expected, the presence of UFH (5 U/ml) increased the initial ACT to 462.3 ± 23.3 s (mean ± s.e.m.) (Fig. 4a) and prevented visually identifiable clot formation in the extracorporeal circuit during the 2-h recirculation period. Scanning electron micrograph (SEM) images of oxygenator membranes post circulation from those circuits also showed minimal fibrinous and cellular debris (Fig. 4b) . The addition of protamine (0.05 mg/ml) to a post-circulation sample restored the ACT to baseline levels in all cases (Fig. 4a) .
GD-FXa S195A (3 µM) Figure 4 Anticoagulant effects during extracorporeal circulation of human blood. (a,b) Whole blood was anticoagulated with one of the following strategies: 5 U/ml UFH (n = 11 independent experiments), 2 µM 11F7t alone (n = 3 independent experiments), 2 µM rivaroxaban alone (n = 3 independent experiments), 2 µM 11F7t plus 2 µM rivaroxaban (n = 9 independent experiments), 2 µM 11F7t plus 2 µM apixaban (n = 8 independent experiments), 2 µM 11F7t plus 2 µM edoxaban (n = 9 independent experiments) or 2 µM 11F7t plus 2 µM fondaparinux (Fonda) (n = 5 independent experiments) before continuous ex vivo circulation for 120 min. ACT levels for each of the indicated anticoagulation strategies were assessed at the following time points: (i) before anticoagulant addition, (ii) before initiation of blood flow within the circuit (t = 0 min), (iii) at 5 min, 60 min and 120 min after circulation and (iv) after antidote addition post-circulation (a). Protamine (0.05 mg/ml) or GD-FXa Ser195Ala (3 µM), respectively, was given to reverse the effects of UFH or each combination of 11F7t plus a FXa catalytic site inhibitor. Representative SEM images (100× (left) and 1,000× (right) magnification) of oxygenator membranes obtained from ex vivo circuits after circulation of whole blood with each of the indicated anticoagulation strategies are shown (b). Scale bars, 50 µm (left), 500 µm (right). (c,d) Blood flow rate (c) and pressure (d) within the circuit were monitored in real-time in a subset of experiments conducted with the indicated combinations of 11F7t and rivaroxaban in comparison to either UFH (5 U/ml), 11F7t (2 µM) or rivaroxaban (2 µM) alone (n = 3 independent experiments per group). Throughout, the data are presented as mean ± s.e.m.
GD-FXa

A r t i c l e s
As predicted by the partial inhibition of thrombin or clot formation in the CAT and TEG assays, respectively, treatment with 11F7t or any of the active site-directed inhibitors of FXa alone failed to provide satisfactory anticoagulation during recirculation. Specifically, clot accumulation was apparent within the circuit reservoir, on the oxygenator membrane or in the circuit tubing ( Supplementary Fig. 7) ; SEM images of oxygenator membranes from these circuits showed significant fibrin and cellular deposition (Fig. 4b) . Moreover, ACT values obtained from each of these strategies failed to exceed 320 s. Clots also formed when circuit blood was anticoagulated by treatment with fondaparinux 7 , another clinically approved FXa inhibitor that on its own was also found to be less effective than UFH (Supplementary Fig. 8 ). In contrast, the combined presence of 2 µM 11F7t plus 2 µM rivaroxaban, apixaban, edoxaban or fondaparinux each prevented visible clot formation in the circuit and resulted in minimal deposition of fibrin and cellular debris on the oxygenator membranes, as assessed by inspection of SEM images (Fig. 4b) . Moreover, consistent with their apparent anticoagulant efficacy, the aforementioned combinations of inhibitors raised the ACT to 512.4 ± 15.1 s, 516.7 ± 12.9 s, 478.5 ± 16.8 s and 375.2 ± 12.6 s, respectively, which remained elevated to a comparable level throughout the 2-h period of continuous circulation (Fig. 4a) . Furthermore, adding GD-FXa Ser195Ala (3 µM) to post-circulation blood samples from those circuits restored the ACT to baseline levels (Fig. 4a) .
To further quantify the efficacy of this dual anti-FXa anticoagulant strategy in the ex vivo oxygenator model, blood pressure and flow rate within the circuit were monitored in real time in a subset of experiments. As expected, when 5 U/ml UFH was used as the anticoagulant, no significant deviation in the initial flow rate (50 ml/min) or pressure was observed throughout the 2-h period of circulation, reflecting the successful maintenance of circuit patency (Fig. 4c,d) . In contrast, when 2 µM rivaroxaban or 2 µM 11F7t was used as the sole anticoagulant, a rapid decrease in flow rate and a concomitant elevation in pressure within the circuit were detected after approximately 20 or 40 min of circulation, respectively, due to the formation of obstructing clots (Fig. 4c,d) . However, similarly to that seen with UFH, the combination of 2 µM 11F7t plus 2 µM rivaroxaban effectively maintained circuit patency without any significant deviation in blood flow rate or pressure (Fig. 4c,d) . These results demonstrated that combinations of 11F7t plus a FXa catalytic site inhibitor could prevent clotting in human blood that was recirculated continuously for 2 h within an ex vivo membrane oxygenator circuit as effectively as UFH and that treatment with GD-FXa Ser195Ala could effectively neutralize the effects of both anticoagulants following circulation.
Patient morbidity associated with UFH-facilitated CPB surgery is partly attributable to intraoperative generation of thrombin, which is commonly measured by assessing circulating levels of prothrombin fragment 1.2 (F1.2), a peptide cleaved from prothrombin during its activation 38 . Pre-circulation levels of F1.2 were within the normal range 39 in blood samples that were subject to anticoagulation with each of the evaluated strategies (0.19 ± 0.02 nM; mean ± s.e.m.). In circuit blood anticoagulated with UFH, F1.2 levels were significantly increased (5.91 ± 1.46 nM, P = 0.0002) following 2 h of recirculation, indicating that substantial thrombin generation had occurred despite the absence of detectable clot formation (Fig. 5) . By contrast, in blood that was anticoagulated by treatment with 2 µM 11F7t plus a 2 µM of a FXa active site inhibitor, mean post-circulation F1.2 levels were <0.5 nM and significantly (P < 0.01) lower than those observed with UFH treatment by greater than tenfold (Fig. 5) . Thus, in human blood subjected to continuous extracorporeal circulation, the combination of 11F7t plus a FXa active site-directed inhibitor not only duplicated UFH's anticoagulant effect, but it was also more effective than UFH in limiting thrombin generation.
For comparison, in circuits that were subjected to anticoagulation with 2 µM 11F7t or 2 µM rivaroxaban alone, under which conditions extensive clotting was observed, post-circulation F1.2 levels in the remaining fluid were 184.5 ± 86.7 nM and 325.4 ± 27.3 nM, respectively, >350-fold higher than the levels observed when the two inhibitors were paired at those same concentrations (Fig. 5) . Finally, post-circulation levels of bradykinin, a pro-inflammatory product of the kallikrein-kinin system that is generated through contact pathway activation and also becomes elevated during UFH-facilitated CPB 40 , were similarly increased in circuits anticoagulated with UFH or each combination of 11F7t plus a FXa active site inhibitor ( Supplementary  Fig. 9) , consistent with the notion that bradykinin generation during CPB is not thrombin dependent and that all of these anticoagulant strategies limit such activation to a similar degree.
Reduction in the risk of HIT antibody-mediated platelet activation
To assess whether administration of 11F7t to a patient with autoantibodies against heparin and platelet factor 4 complexes (hereafter referred to as HIT antibodies) would elicit pathological platelet activation, as normally occurs after treatment with UFH, we compared the ability of purified IgG from three patients with a clinical diagnosis of HIT to induce platelet aggregation in the presence of UFH or 11F7t, alone or in combination with a FXa active site inhibitor. Purified IgG (25-100 µg/ml) from all three patients with HIT consistently caused UFH-dependent platelet aggregation in PRP, with a maximum light transmission (Mx%) of 79 ± 15% (mean ± s.e.m.) in the presence of 2 U/ml UFH (Supplementary Fig. 10 ). In contrast, HIT IgG-triggered platelet activation was not observed when UFH was replaced by a range of 11F7t concentrations (0.1 to 5.0 µM) with or without the additional presence of either edoxaban or fondaparinux (Supplementary Fig. 10 ).
DISCUSSION
Our finding that multistep inhibition of coagulation is key for generating robust anticoagulation is consistent with prior studies demonstrating Figure 5 Thrombin generation during extracorporeal circulation of human blood. Pre-and post-circulation levels of plasma F1.2 were measured after whole blood was anticoagulated with one of the following strategies before continuous ex vivo recirculation for 120 min: 5 U/ml UFH (n = 10 independent experiments), 2 µM 11F7t alone (n = 3 independent experiments), 2 µM rivaroxaban alone (n = 3 independent experiments), 2 µM 11F7t plus 2 µM rivaroxaban (n = 9 independent experiments), 2 µM 11F7t plus 2 µM apixaban (n = 6 independent experiments), 2 µM 11F7t plus 2 µM edoxaban (n = 7 independent experiments) or 2 µM 11F7t plus 2 µM fondaparinux (n = 6 independent experiments). Data are presented as mean ± s.e.m. Statistical analysis was performed by one-way ANOVA followed by Tukey's multiplecomparisons test.
A r t i c l e s that aptamer-mediated inhibition of individual procoagulant proteases is not sufficient for preventing clotting during extracorporeal circulation 26 . For example, although we previously showed that an aptamer targeting factor IXa could successfully replace UFH in a neonatal porcine model of CPB surgery 41 , evidence of gross thrombus formation was readily seen when the same aptamer was used either for CPB anticoagulation in adult pigs (unpublished data) and baboons 42 or during circulation of human blood in an ex vivo oxygenator circuit identical to that used in the present study 26 . This example also highlights the value of such an ex vivo circulation model as a stringent predictor of the potential efficacy of an anticoagulation strategy for in vivo CPB surgery. In fact, before our current study, only a handful of other anticoagulants besides UFH have been reported to prevent clot formation in human blood subjected to similar circulation within an ex vivo oxygenator circuit 43, 44 . Among these are certain low-molecularweight heparins, such as enoxaparin, the thrombin-specific inhibitor hirudin 44 and the FXa-specific inhibitor tick anticoagulant peptide 43 . Nevertheless, with each of these anticoagulants, investigators noted that circulating markers of thrombin generation or activity were either similarly increased or elevated as compared to those seen with UFH 43, 44 . Hence, our finding that the combination of 11F7t plus a FXa active site inhibitor suppresses post-circulation F1.2 levels considerably more than UFH supports the idea that minimizing thrombin formation by inhibiting multiple upstream procoagulant steps is not only an effective approach for achieving UFH-like anticoagulation, but it may also reduce the risk of common clinical complications of UFH-facilitated CPB exacerbated by thrombin's pro-thrombotic and pro-inflammatory activities 3, 4, 45 . These include CPB-related systemic inflammatory response syndrome (SIRS) 5,9,15 , thromboembolism 4, 11, 12, 17 , ischemia-reperfusion injury 4, 5, 46 , consumptive coagulopathy 3,4,11,17 and platelet dysfunction 4, 5, 8, 10, 11 .
We also demonstrate that the FXa mutant GD-FXa Ser195Ala can simultaneously reverse the anticoagulant effects of 11F7t plus an active site-directed inhibitor of FXa. GD-FXa Ser195Ala is nearly identical in sequence to the recombinant FXa mutant, andexanet alfa, which is efficacious as a reversal agent for direct and indirect FXa inhibitors 28, 29 and has received clinical approval by the US Food and Drug Administration (FDA) in May 2018. Thus, our findings suggest that andexanet alfa may have additional applicability as an antidote for 11F7t, when used either by itself or in combination dosing strategies.
Although the direct thrombin inhibitor bivalirudin has been used as an alternative CPB anticoagulant to UFH in patients with proven or suspected HIT, bivalirudin requires continuous infusion owing to its 25-min half-life, and its use during CPB surgery carries a well-known risk of clot formation in blood that becomes stagnant in the operative field or in the CPB circuit 2, 3 . Although bivalirudin is approved for CPB surgery in Canada, it has not received approval by the US FDA or the European Medicines Agency (EMA), even for patients with HIT. At our institution, patients with known or suspected HIT who require CPB are treated by attempting to remove HIT antibodies by blood apheresis before surgery, an expensive and time-consuming process, to allow for UFH use during CPB and to avoid using bivalirudin. Although a prior report suggested that certain nucleic acid aptamers can bind patientderived HIT antibodies analogously to UFH to induce immunogenic platelet activation 47 , we did not observe this with 11F7t or any combination of 11F7t plus an active site-directed FXa inhibitor.
Given that clinical CPB necessitates infusion of an intravenous anticoagulant, it must be noted that each of the three direct FXa active site inhibitors tested in this study (rivaroxaban, apixaban and edoxaban) is only approved for oral administration and requires solubilization in dimethylsulfoxide (DMSO) for in vitro or ex vivo testing. The findings of this study may encourage the reformulation of one of the above agents for intravenous administration. Additionally, further assessment of the combination of 11F7t and an active site-directed inhibitor of FXa, together with their antidote(s), as a CPB anticoagulation strategy requires preclinical studies in mammals that are large enough to undergo cardiac procedures. Because 11F7t does not effectively inhibit canine, porcine or bovine FXa, evaluating the efficacy of this strategy necessitates studies on nonhuman primates.
The use of nucleic acid aptamers to complement existing smallmolecule drugs directed against the catalytic site of the same enzyme may be a generalized approach for identifying potent combinatorial therapies in a variety of clinical contexts. This is because aptamerbased therapies typically engage their targets by burying large surfaceexposed regions and blocking exosite-dependent macromolecular interactions 48 , in contrast to the mechanism of action of catalytic site-directed inhibitors such as small-molecule drugs. For example, we recently showed in vitro that the concomitant presence of distinct RNA aptamers specific for the G protein-coupled receptor β2-adrenoceptor could selectively stabilize the binding of small-molecule β2-adrenoreceptor drug agonists or antagonists, respectively, in an allosteric fashion 49 . Thus, our overall findings not only suggest promising avenues for developing improved alternatives to UFH for potent, antidote-controllable anticoagulation, but they also highlight generalizable strategies for identifying effective combinatorial treatments for other important therapeutic applications on the basis of the ability of aptamers to complement agents from other drug classes.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Structure of the 11F7t-GD-Xa Ser195Ala complex. Equivalent binding constants observed for the interaction of 11F7t with GD-FXa Ser195Ala or wild-type FXa imply that the details revealed here adequately model the essential features of its interaction with wild-type FXa 25 . GD-FXa Ser195Ala was dialyzed into 20 mM HEPES, 0.15 M NaCl and 5 mM Ca 2+ , concentrated to ~13 mg/ml by centrifugal ultrafiltration (Amicon Ultra-15, Millipore) and stored in aliquots at −80 °C. A concentrated solution of 11F7t was also dialyzed into the same buffer. For crystallization trials, GD-FXa Ser195Ala was mixed with small volumes of 11F7t and rivaroxaban to achieve two equivalents of aptamer per mole of proteinase in either the absence or presence of one equivalent of rivaroxaban. Trials were conducted by vapor diffusion at room temperature using sitting-drop plates (Cryschem M, Hampton Research), with 500 µl precipitant in the reservoir, and by mixing 1 µl of the complexes of 11F7t-GD-FXa Ser195Ala or 11F7t-GD-FXa Ser195Ala -rivaroxaban with 1 µl of the precipitant solution. The final concentrations were 67 µM GD-FXa Ser195Ala and 134 µM 11F7t or 62.5 µM GD-FXa Ser195Ala , 125 µM 11F7t and 75 µM rivaroxaban in the initial drop. Crystals for either complex appeared in several conditions within 4-6 d. Those appearing with Morpheus Screen condition 2-33 (Molecular Dimensions) were cryoprotected using the same buffer containing 20% (vol/vol) glycerol and used for data collection. Final data sets were collected on crystals obtained in 0.1 M bicine, 0.1 M Tris base, pH 8.5 with 0.1 M carboxylic acids (0.1 M each of sodium formate, ammonium acetate, tribasic sodium citrate dihydrate, sodium potassium tartarate tetrahydrate and sodium oxamate), 10% (wt/vol) polyethylene glycol (PEG) 20,000 and 20% (vol/vol) PEG 500 monomethyl ester. Diffraction data were collected at 100 °K either at the NE-CAT 24-ID-C beamline at APS (λ = 0.9793 Å) for GD-FXa Ser195Ala /11F7t with a Pilatus 6M detector or at the Univ. of Pennsylvania X-ray facility equipped with a Rigaku MicroMax-007 HF generator (λ = 1.5418 Å) and a MAR imaging plate for GD-FXa Ser195Ala /11F7t/rivaroxaban. Diffraction data were processed with DENZO or XDS 61, 62 . Data were minimally truncated to give I/Iσ significantly larger than 1 in the highest-resolution cell. A starting structure was solved by molecular replacement using Phaser and the highest resolution published structure for GD-FXa (Protein Data Bank (PDB) ID 2Y5G) 63 . The aptamer and rivaroxaban were manually built into unaccounted density following molecular replacement of the polypeptide. Ca 2+ and Na + were placed in the polypeptide structure based on density and the known binding sites for these cations to the proteinase domain. Two Mg 2+ atoms were placed in the aptamer structure based on observed density and the requirement of 1 mM Mg 2+ for aptamer re-annealing before use 34 . Automated refinement was performed with the Phenix suite (ver. 1.13-2998) of programs 64 . The aptamer was refined using ERRASER under Rosetta, which is included in the Phenix suite 65 . Manual model building and refinement were done by using Coot (ver. 0.8.8) 66 . A final cycle of refinement with automated parameter selection was performed using PDB_REDO (REFMAC 5.8.0210) to provide readily reproducible fitted models and statistics 67 . Interacting residues on the aptamer and protein were analyzed by using PISA (ver. 1.51) 68 . Final structural models were validated using Molprobity and visualized using Pymol (ver. 2.04) 69, 70 .
Progress curves for FXa-initiated prothrombin activation. Thrombin generation in reaction mixtures (200 µl) containing 1.4 µM prothrombin, 9 nM FVa, 30 µM PCPS, with or without varying concentrations of 11F7t and/or apixaban at 25 °C was initiated by adding 0.2 nM FXa. Activity measurements were performed in an assay buffer consisting of 20 mM HEPES, 150 mM NaCl, 5 mM CaCl 2 , 0.1% (wt/vol) and PEG 8000, pH 7.5. Prior to addition, the aptamer was diluted in assay buffer, heated to 65 °C for 5 min and cooled to ambient temperature for 3 min to renature the RNA. 10-µl aliquots were removed at various time points after reaction initiation and quenched by mixing with 90 µl of assay buffer lacking Ca 2+ but containing 50 mM EDTA, followed by further dilution (1:10) in the same buffer. After addition of 100 µM S2238, initial rates of peptidyl substrate cleavage were calculated based on the change in absorbance (405 nm) by using a Gemini kinetic plate reader (Molecular Devices). Initial rates of S2238 cleavage were determined based on the linear appearance of product as a function of time, which were then converted to rates of thrombin formation based on the linear relationship between this initial rate and known concentrations of thrombin.
Progress curves for FIXa-initiated prothrombin activation. Assays were performed exactly as described above for prothrombin cleavage by prothrombinase, except that reaction mixtures (200 µl) contained 1.4 µM prothrombin, 110 nM FX, 0.9 nM FVIII, 9 nM FVa, 30 µM PCPS, with or without varying concentrations of 11F7t and/or apixaban at 25 °C, and thrombin generation was initiated with 2 nM FIXaβ. For inhibitor neutralization assays, varying concentrations of GD-FXa Ser195Ala or AO5-2 were added to the reaction mixture after inclusion of all of the other reaction components and before initiation with FIXaβ. The sigmoidal progress curve for thrombin formation in this system (Fig. 2c) arises from the slow rate of FXa formation catalyzed by FIXa alone, the subsequent amplification of FXa formation following assembly of intrinsic tenase resulting from activation of FVIII by FXa and/or traces of thrombin, and the explosive generation of thrombin after assembly of prothrombinase. Given the complexity of the system, empirical measures of the time required to generate 10 nM thrombin (Fig. 2d) or the concentration of thrombin produced at 10 min following initiation (Fig. 2e) were used to assess the inhibitory effects of apixaban and 11F7t added alone and in combination.
Blood. For thrombin-generation, TEG, extracorporeal membrane oxygenator circuit and platelet-aggregation studies, blood was drawn from healthy volunteers, from whom informed consent was obtained in all cases under a Duke University Institutional Review Board (IRB)-approved protocol, in which blood draw procedures were in accordance with institutional guidelines. Blood was anticoagulated with 3.2% sodium citrate unless otherwise noted.
Calibrated automated thrombography (CAT).
Citrated whole blood from healthy donors was obtained as described above and centrifuged at 180g for 20 min to isolate PRP. In Immunlon 2HB clear U-bottom 96-well plates (Thermo Labsystems), PRP (80 µl) was mixed with 10 µl of anticoagulant (either UFH or 11F7t with or without a FXa catalytic site inhibitor) and incubated at 37 °C for 5 min. Prior to addition, 11F7t was diluted in HEPES-saline assay buffer 1 nature research | reporting summary The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Data analysis
Commercially available Graphpad Prism 7 and JMP Pro 12 were used for statistical analysis as indicated in the Methods section. Thrombinoscope software (Thrombinoscope BV) was used for analysis of CAT data TEG Analytical Software version 4.2.3 (Haemonetics) was used for analysis of TEG data LabChart 7 software (AD Instruments) was used for analysis of extracorporeal circulation studies. Phenix suite (Ver. 1.13-2998), Rosetta (included in the Phenix suite), Coot (Ver. 0.8.8), PDB_REDO (REFMAC 5.8.0210), PISA (Ver. 1.51), and Pymol (Ver. 2.04) softwares were used for crystallography analysis.
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Crystallographic data have been deposited in the Protein Data Bank under accession codes 5VOE (11F7t:dG-XaS195A) and 5VOF (11F7t:dG-XaS195A:Rivaroxaban).
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Sample size
No studies (ex. animal studies) that require precise pre-calculation of required sample size were performed in this work. For all studies, the exact sample size (n) of each experiment is included in the figure, figure legend, or table legends in the main manuscript and supplementary information files. For in vitro and ex vivo experiments, our routine practice is conduct at least 3 independent experiments, typically with at least 2 or 3 biological replicates, which is standard practice in the field.
Data exclusions No data were excluded from analyses.
Replication
All attempts at replication were successful. For CAT, TEG, and ex vivo CPB studies involving plasma or blood samples from healthy volunteers, all experimental conditions were also tested using samples from at least three different donors for further stringency.
